IL1B and Alzheimer disease: In addition, SGLT2is physiologically elevates blood ketone bodies such as β-hydroxybutyrate (Kim et al., 2019), which can modulate NLRP3 inflammasome-IL-1β signaling (Kim et al., 2020), a key pathologic pathway in AD (Heneka et al., 2013).